nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

06.08.2022 | Review – Clinical Oncology

Early T-cell precursor lymphoblastic leukemia accompanied by prominent blastic plasmacytoid dendritic cell proliferation mimicking blastic plasmacytoid dendritic cell neoplasm: an exceptional case report and literature review

verfasst von: Hongyan Liao, Jiang Yu, Yu Liu, Sha Zhao, Huanling Zhu, Dongsheng Xu, Nenggang Jiang, Qin Zheng

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 10/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Plasmacytoid dendritic cells (pDCs) are commonly associated with myeloid malignancies. The association between lymphoblastic leukemia and pDCs has been little explored.

Case presentation

Here, we report a novel case of early T-cell precursor lymphoblastic leukemia (ETP-ALL) accompanied by prominent proliferation of blastic pDCs mimicking BPDCN. The diagnosis was established based on a comprehensive analysis of morphology, immunophenotype and clinical implications. We also present a literature review and discussion on the differential expression of reactive and neoplastic pDCs, the functional role of pDCs in lymphoblastic leukemia, and the etiological association of normal pDCs and BPDCN.

Conclusions

The current case demonstrates for the first time that prominent pDC proliferation can be associated with lymphoid neoplasms and can exhibit blastic morphology and immunophenotype. The underlying mechanism of the coexistence of these two blastic populations remains unknown. Further genetic profiling may be required to denote the progressive development of tumor stem cells to the lymphoid, myeloid or dendritic cell lineage. Moreover, the prognostic value of pDCs in hematological neoplasms needs further investigation.

Alayed K, Patel KP, Konoplev S, Singh RR, Routbort MJ, Reddy N et al (2013) TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol 88(12):1055–1061. https://doi.org/10.1002/ajh.23567CrossRefPubMed

Bond J, Graux C, Lhermitte L, Lara D, Cluzeau T, Leguay T et al (2017) Early response-based therapy stratification improves survival in adult early thymic precursor acute lymphoblastic leukemia: a group for research on adult acute lymphoblastic leukemia study. J Clin Oncol off J Am Soc Clin Oncol 35(23):2683–2691. https://doi.org/10.1200/JCO.2016.71.8585CrossRef

Cordeau M, Belounis A, Lelaidier M, Cordeiro P, Sartelet H, Herblot S et al (2016) Efficient killing of high risk neuroblastoma using natural killer cells activated by plasmacytoid dendritic cells. PLoS One 11(10):e0164401. https://doi.org/10.1371/journal.pone.0164401CrossRefPubMedPubMedCentral

Cota C, Vale E, Viana I, Requena L, Ferrara G, Anemona L et al (2010) Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm-morphologic and phenotypic variability in a series of 33 patients. Am J Surg Pathol 34(1):75–87. https://doi.org/10.1097/PAS.0b013e3181c5e26bCrossRefPubMed

Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D et al (2009) Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 10(2):147–156. https://doi.org/10.1016/S1470-2045(08)70314-0CrossRefPubMedPubMedCentral

Dalle S, Beylot-Barry M, Bagot M, Lipsker D, Machet L, Joly P et al (2010) Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol 162(1):74–79. https://doi.org/10.1111/j.1365-2133.2009.09373.xCrossRefPubMed

Dargent JL, Delannoy A, Pieron P, Husson B, Debecker C, Petrella T (2011) Cutaneous accumulation of plasmacytoid dendritic cells associated with acute myeloid leukemia: a rare condition distinct from blastic plasmacytoid dendritic cell neoplasm. J Cutan Pathol 38(11):893–898. https://doi.org/10.1111/j.1600-0560.2011.01777.xCrossRefPubMed

Derolf AR, Laane E, Bjorklund E, Saft L, Bjorkholm M, Porwit A (2014) Dendritic cells in bone marrow at diagnosis and after chemotherapy in adult patients with acute myeloid leukaemia. Scand J Immunol 80(6):424–431. https://doi.org/10.1111/sji.12223CrossRefPubMed

Diaz-Rodriguez Y, Cordeiro P, Belounis A, Herblot S, Duval M (2017) In vitro differentiated plasmacytoid dendritic cells as a tool to induce anti-leukemia activity of natural killer cells. Cancer Immunol Immunother 66(10):1307–1320. https://doi.org/10.1007/s00262-017-2022-yCrossRefPubMedPubMedCentral

Facchetti F, Cigognetti M, Fisogni S, Rossi G, Lonardi S, Vermi W (2016) Neoplasms derived from plasmacytoid dendritic cells. Mod Pathol off J U S Can Acad Pathol Inc 29(2):98–111. https://doi.org/10.1038/modpathol.2015.145CrossRef

Feuillard J, Jacob MC, Valensi F, Maynadie M, Gressin R, Chaperot L et al (2002) Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood 99(5):1556–1563. https://doi.org/10.1182/blood.v99.5.1556CrossRefPubMed

Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE et al (2014) Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood 124(3):385–392. https://doi.org/10.1182/blood-2014-04-566737CrossRefPubMedPubMedCentral

Fu Y, Fesler M, Mahmud G, Bernreuter K, Jia D, Batanian JR (2013) Narrowing down the common deleted region of 5q to 6.0 Mb in blastic plasmacytoid dendritic cell neoplasms. Cancer Genet 206(7–8):293–298. https://doi.org/10.1016/j.cancergen.2013.07.002CrossRefPubMed

Gabrilovich D (2004) Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 4(12):941–952. https://doi.org/10.1038/nri1498CrossRefPubMed

Grouard G, Rissoan MC, Filgueira L, Durand I, Banchereau J, Liu YJ (1997) The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J Exp Med 185(6):1101–1111. https://doi.org/10.1084/jem.185.6.1101CrossRefPubMedPubMedCentral

Harvell JD, Fulton R, Jones CD, Terris DJ, Warnke RA (2000) Composite dendritic cell neoplasm (NOS) and small lymphocytic lymphoma. Appl Immunohistochem Mol Morphol 8(4):322–328PubMed

Herling M, Teitell MA, Shen RR, Medeiros LJ, Jones D (2003) TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin. Blood 101(12):5007–5009. https://doi.org/10.1182/blood-2002-10-3297CrossRefPubMed

Ishikawa F, Niiro H, Iino T, Yoshida S, Saito N, Onohara S et al (2007) The developmental program of human dendritic cells is operated independently of conventional myeloid and lymphoid pathways. Blood 110(10):3591–3660. https://doi.org/10.1182/blood-2007-02-071613CrossRefPubMedPubMedCentral

Jain N, Lamb AV, O’Brien S, Ravandi F, Konopleva M, Jabbour E et al (2016) Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood 127(15):1863–1869. https://doi.org/10.1182/blood-2015-08-661702CrossRefPubMedPubMedCentral

Jegalian AG, Facchetti F, Jaffe ES (2009) Plasmacytoid dendritic cells: physiologic roles and pathologic states. Adv Anat Pathol 16(6):392–404. https://doi.org/10.1097/PAP.0b013e3181bb6bc2CrossRefPubMedPubMedCentral

Jing Y, Shaheen E, Drake RR, Chen N, Gravenstein S, Deng Y (2009) Aging is associated with a numerical and functional decline in plasmacytoid dendritic cells, whereas myeloid dendritic cells are relatively unaltered in human peripheral blood. Hum Immunol 70(10):777–784. https://doi.org/10.1016/j.humimm.2009.07.005CrossRefPubMedPubMedCentral

Julia F, Dalle S, Duru G, Balme B, Vergier B, Ortonne N et al (2014) Blastic plasmacytoid dendritic cell neoplasms: clinico-immunohistochemical correlations in a series of 91 patients. Am J Surg Pathol 38(5):673–680. https://doi.org/10.1097/PAS.0000000000000156CrossRefPubMed

Karsunky H, Merad M, Mende I, Manz MG, Engleman EG, Weissman IL (2005) Developmental origin of interferon-alpha-producing dendritic cells from hematopoietic precursors. Exp Hematol 33(2):173–181. https://doi.org/10.1016/j.exphem.2004.10.010CrossRefPubMed

Khan AM, Munir A, Raval M, Mehdi S (2019) Blastic plasmacytoid dendritic cell neoplasm in the background of myeloproliferative disorder and chronic lymphocytic leukaemia. BMJ Case Rep. https://doi.org/10.1136/bcr-2019-230332CrossRefPubMedPubMedCentral

Khoury JD, Medeiros LJ, Manning JT, Sulak LE, Bueso-Ramos C, Jones D (2002) CD56(+) TdT(+) blastic natural killer cell tumor of the skin: a primitive systemic malignancy related to myelomonocytic leukemia. Cancer 94(9):2401–2408. https://doi.org/10.1002/cncr.10489CrossRefPubMed

Laane E, Bjorklund E, Mazur J, Lonnerholm G, Soderhall S, Porwit A (2007) Dendritic cell regeneration in the bone marrow of children treated for acute lymphoblastic leukaemia. Scand J Immunol 66(5):572–583. https://doi.org/10.1111/j.1365-3083.2007.02007.xCrossRefPubMed

Lucas N, Duchmann M, Rameau P, Noel F, Michea P, Saada V et al (2019) Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia. Leukemia 33(10):2466–2480. https://doi.org/10.1038/s41375-019-0447-3CrossRefPubMed

Ma M, Wang X, Tang J, Xue H, Chen J, Pan C et al (2012) Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia. Front Med 6(4):416–420. https://doi.org/10.1007/s11684-012-0224-4CrossRefPubMed

Maecker B, Mougiakakos D, Zimmermann M, Behrens M, Hollander S, Schrauder A et al (2006) Dendritic cell deficiencies in pediatric acute lymphoblastic leukemia patients. Leukemia 20(4):645–649. https://doi.org/10.1038/sj.leu.2404146CrossRefPubMed

Mami NB, Mohty M, Chambost H, Gaugler B, Olive D (2004) Blood dendritic cells in patients with acute lymphoblastic leukaemia. Br J Haematol 126(1):77–80. https://doi.org/10.1111/j.1365-2141.2004.04989.xCrossRefPubMed

Menezes J, Acquadro F, Wiseman M, Gomez-Lopez G, Salgado RN, Talavera-Casanas JG et al (2014) Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. Leukemia 28(4):823–829. https://doi.org/10.1038/leu.2013.283CrossRefPubMed

Milley S, Thomas L, Balme B, Dalle S (2016) Blastic plasmacytoid dendritic cell neoplasm following Waldenstrom macroglobulinemia. J Eur Acad Dermatol Venereol 30(5):904–905. https://doi.org/10.1111/jdv.13074CrossRefPubMed

Neumann M, Heesch S, Schlee C, Schwartz S, Gokbuget N, Hoelzer D et al (2013) Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations. Blood 121(23):4749–4752. https://doi.org/10.1182/blood-2012-11-465138CrossRefPubMed

Petrella T, Facchetti F (2010) Tumoral aspects of plasmacytoid dendritic cells: what do we know in 2009? Autoimmunity 43(3):210–214. https://doi.org/10.3109/08916930903510898CrossRefPubMed

Petrella T, Bagot M, Willemze R, Beylot-Barry M, Vergier B, Delaunay M et al (2005) Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol 123(5):662–675CrossRef

Reichard KK, Burks EJ, Foucar MK, Wilson CS, Viswanatha DS, Hozier JC et al (2005) CD4(+) CD56(+) lineage-negative malignancies are rare tumors of plasmacytoid dendritic cells. Am J Surg Pathol 29(10):1274–1283. https://doi.org/10.1097/01.pas.0000172194.32918.5cCrossRefPubMed

Renosi F, Roggy A, Giguelay A, Soret L, Viailly PJ, Cheok M et al (2021) Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis. Blood Adv 5(5):1540–1551. https://doi.org/10.1182/bloodadvances.2020003359CrossRefPubMedPubMedCentral

Rissoan MC, Soumelis V, Kadowaki N, Grouard G, Briere F, de Waal MR et al (1999) Reciprocal control of T helper cell and dendritic cell differentiation. Science 283(5405):1183–1186. https://doi.org/10.1126/science.283.5405.1183CrossRefPubMed

Sapienza MR, Fuligni F, Agostinelli C, Tripodo C, Righi S, Laginestra MA et al (2014) Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition. Leukemia 28(8):1606–1616. https://doi.org/10.1038/leu.2014.64CrossRefPubMedPubMedCentral

Sawant A, Hensel JA, Chanda D, Harris BA, Siegal GP, Maheshwari A et al (2012) Depletion of plasmacytoid dendritic cells inhibits tumor growth and prevents bone metastasis of breast cancer cells. J Immunol 189(9):4258–4265. https://doi.org/10.4049/jimmunol.1101855CrossRefPubMed

Song HL, Huang WY, Chen YP, Chang KC (2012) Tumorous proliferations of plasmacytoid dendritic cells and Langerhans cells associated with acute myeloid leukaemia. Histopathology 61(5):974–983. https://doi.org/10.1111/j.1365-2559.2012.04282.xCrossRefPubMed

Sozzani S, Vermi W, Del Prete A, Facchetti F (2010) Trafficking properties of plasmacytoid dendritic cells in health and disease. Trends Immunol 31(7):270–277. https://doi.org/10.1016/j.it.2010.05.004CrossRefPubMed

Steven H, Swerdlow EC, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, Siebert R (2017) WHO Classification of tumours of haematopoietic and lymphoid tissues (Revised, 4th edn. International Agency for Research on Cancer, Lyon, France

Tang Z, Tang G, Wang SA, Lu X, Young KH, Bueso-Ramos CE et al (2016) Simultaneous deletion of 3’ETV6 and 5’EWSR1 genes in blastic plasmacytoid dendritic cell neoplasm: case report and literature review. Mol Cytogenet 9:23. https://doi.org/10.1186/s13039-016-0232-1CrossRefPubMedPubMedCentral

Tang Z, Li Y, Wang W, Yin CC, Tang G, Aung PP et al (2018) Genomic aberrations involving 12p/ETV6 are highly prevalent in blastic plasmacytoid dendritic cell neoplasms and might represent early clonal events. Leuk Res 73:86–94. https://doi.org/10.1016/j.leukres.2018.09.006CrossRefPubMed

Trimoreau F, Donnard M, Turlure P, Gachard N, Bordessoule D, Feuillard J (2003) The CD4+ CD56+ CD116- CD123+ CD45RA+ CD45RO- profile is specific of DC2 malignancies. Haematologica 88(3):ELT10PubMed

Triplett TA, Cardenas KT, Lancaster JN, Hu Z, Selden HJ, Jasso GJ et al (2016) Endogenous dendritic cells from the tumor microenvironment support T-ALL growth via IGF1R activation. Proc Natl Acad Sci U S A 113(8):E1016-1025. https://doi.org/10.1073/pnas.1520245113CrossRefPubMedPubMedCentral

Vermi W, Facchetti F, Rosati S, Vergoni F, Rossi E, Festa S et al (2004) Nodal and extranodal tumor-forming accumulation of plasmacytoid monocytes/interferon-producing cells associated with myeloid disorders. Am J Surg Pathol 28(5):585–595. https://doi.org/10.1097/00000478-200405000-00004CrossRefPubMed

Vitte F, Fabiani B, Benet C, Dalac S, Balme B, Delattre C et al (2012) Specific skin lesions in chronic myelomonocytic leukemia: a spectrum of myelomonocytic and dendritic cell proliferations: a study of 42 cases. Am J Surg Pathol 36(9):1302–1316. https://doi.org/10.1097/PAS.0b013e31825dd4deCrossRefPubMed

Wang M, Chen YJ, Wang LR, Wang YZ, Lu J (2018) Plasmacytoid dendritic cells proliferation coexisted with acute myeloid leukemia. Chin Med J 131(15):1866–1867. https://doi.org/10.4103/0366-6999.237404CrossRefPubMedPubMedCentral

Wang P, Feng Y, Deng X, Liu S, Qiang X, Gou Y et al (2017) Tumor-forming plasmacytoid dendritic cells in acute myelocytic leukemia: a report of three cases and literature review. Int J Clin Exp Pathol 10(7):7285–7291PubMedPubMedCentral

Xiao W, Goldberg AD, Famulare CA, Devlin SM, Nguyen NT, Sim S et al (2019) Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia. Haematologica 104(7):1378–1387. https://doi.org/10.3324/haematol.2018.203018CrossRefPubMedPubMedCentral

Xiao W, Chan A, Waarts MR, Mishra T, Liu Y, Cai SF et al (2021) Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia. Blood 137(10):1377–1391. https://doi.org/10.1182/blood.2020007897CrossRefPubMedPubMedCentral

Yang GX, Lian ZX, Kikuchi K, Moritoki Y, Ansari AA, Liu YJ et al (2005) Plasmacytoid dendritic cells of different origins have distinct characteristics and function: studies of lymphoid progenitors versus myeloid progenitors. J Immunol 175(11):7281–7287. https://doi.org/10.4049/jimmunol.175.11.7281CrossRefPubMed

Yu H, Zhang P, Yin X, Yin Z, Shi Q, Cui Y et al (2015) Human BDCA2+CD123+CD56+ dendritic cells (DCs) related to blastic plasmacytoid dendritic cell neoplasm represent a unique myeloid DC subset. Protein Cell 6(4):297–306. https://doi.org/10.1007/s13238-015-0140-xCrossRefPubMedPubMedCentral

Zalmai L, Viailly PJ, Biichle S, Cheok M, Soret L, Angelot-Delettre F et al (2021) Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape. Haematologica 106(12):3056–3066. https://doi.org/10.3324/haematol.2020.253740CrossRefPubMed

Zhou Z, Lin W, Li X, Huang Y, Ren J, Gao Y et al (2019) Aberrant phenotype and function of dendritic cells in adult B lineage acute lymphoblastic leukemia. Immunol Invest 48(8):781–793. https://doi.org/10.1080/08820139.2019.1610428CrossRefPubMed

Zhu L, Wang P, Zhang W, Li Q, Xiong J, Li J et al (2020) Plasmacytoid dendritic cell infiltration in acute myeloid leukemia. Cancer Manag Res 12:11411–11419. https://doi.org/10.2147/CMAR.S260825CrossRefPubMedPubMedCentral

Titel: Early T-cell precursor lymphoblastic leukemia accompanied by prominent blastic plasmacytoid dendritic cell proliferation mimicking blastic plasmacytoid dendritic cell neoplasm: an exceptional case report and literature review
verfasst von: Hongyan Liao
Jiang Yu
Yu Liu
Sha Zhao
Huanling Zhu
Dongsheng Xu
Nenggang Jiang
Qin Zheng
Publikationsdatum: 06.08.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 10/2022
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-022-04238-0

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Early T-cell precursor lymphoblastic leukemia accompanied by prominent blastic plasmacytoid dendritic cell proliferation mimicking blastic plasmacytoid dendritic cell neoplasm: an exceptional case report and literature review

Abstract

Purpose

Case presentation

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Case presentation

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2022

M6A regulator expression patterns predict the immune microenvironment and prognosis of non-small cell lung cancer

What would one of the greatest natural scientists and educators of the eighteenth century, Georg Christoph Lichtenberg, say about the current therapy management of patients with penile cancer?

GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and/or recurrent neuroblastoma in pediatric patients

Self-efficacy in relation to the use of complementary and alternative medicine, lifestyle choices and cancer aetiology

Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer

Trends of cancer mortality in Xi’an City, China: 2005–2020

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie